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Abstract
Background: In recent years T cell based interferon gamma release assays (IGRA) have been developed for
immunodiagnosis of M. tuberculosis infection. At present these assays do not discriminate between disease and latency.
Therefore, more promising antigens and diagnostic tools are continuously being searched for tuberculosis immunodiag-
nostics. The heparin binding hemagglutinin (HBHA) is a surface protein of M. tuberculosis which promotes bacterial
aggregation and adhesion to non-phagocytic cells. It has been previously assumed that native, methylated form of this
protein would be a promising antigen to discriminate latent from active infection.
Methodology and Principal Findings: We performed a pilot investigation to study humoral and T-cell mediated
immunological responses to recombinant HBHA produced in M. smegmatis or to synthetic peptides in patients with recent
or past tuberculosis, with atypical mycobacteriosis, or in healthy vaccinated individuals. The T cell reactivities to HBHA were
compared to the respective reactivities towards Purified Protein Derivative (PPD) and two surface secreted proteins, ie. Early
Secretory Antigen Target-6 (ESAT-6) and Culture Filtrate Protein-10 (CFP-10). Our pilot results indicate that methylated
recombinant HBHA induced a strong T cell mediated immune response and the production of IgG and IgM-class antibodies
in all patient groups, most surprisingly in young Finnish vaccinees, as well. We observed a positive correlation between the
reactivities to HBHA and non-specific PPD among all studied subjects. As expected, ESAT-6 and CFP-10 were the most
powerful antigens to discriminate disease from immunity caused by vaccination.
Conclusions: On the basis of results of this exploratory investigation we raise concerns that in countries like Finland, where
BCG vaccination was routinely used, HBHA utility might not be sufficient for diagnostics because of inability to explicitly
discriminate tuberculosis infection from immunoreactivity caused by previous BCG vaccination.
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Introduction
Newly introduced T cell based interferon gamma release assays
(IGRA) are of a great diagnostic importance in distinguishing with
high specificity the persons who are infected with Mycobacterium
tuberculosis [1]. These assays, however, do not discriminate between
disease and latent tuberculosis infection (LTBI) [2]. This limitation
lowers their clinical utility e.g. in aging persons originating from a
country with a previously high tuberculosis burden who present
with pulmonary infiltrates or other manifestations suggestive of
tuberculosis reactivation. Therefore, more promising antigens or
diagnostic algorithms are continuously being searched to improve
the current armament for tuberculosis (TB) immunodiagnostics.
Mycobacterium tuberculosis heparin binding hemagglutinin (HBHA) is
a virulence factor that promotes bacterial aggregation, adhesion to
the heparan sulphate proteoglycans of nonphagocytic cells, and
dissemination of tubercle bacilli from the lungs to other tissues in
patients suffering from tuberculosis [3,4]. Locht et al. [3] found
that latently infected humans mount a strong Th1-type immune
response to HBHA, whereas patients with active disease do not.
Moreover, patients with active tuberculosis may develop a strong
humoral response to native methylated HBHA [5,6]. The
diagnostic utility of HBHA-based interferon gamma release assays
(IGRAs) has been further evaluated in Belgium [7], a country with
low tuberculosis (TB) incidence where bacille Calmette et Gue´rin
(BCG) vaccinations are rarely used. In that work, HBHA-based
IGRA was not influenced by prior BCG vaccination and was
significantly more sensitive than Early Secretory Antigen Target-6
(ESAT-6)-based IGRA.
Because some earlier studies [5,7] concluded that previous BCG
vaccination does not influence the assay performance we
wondered whether HBHA-based methods would retain their
diagnostic potential also in Finland. Our country currently has a
low incidence of TB (6,1/100 000 [8]) but our population bore a
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high TB burden as recently as four decades ago. Moreover, since
early fifties till September 2006, 98% of the Finnish population
have been vaccinated. The rationale for this exploratory
investigation was to compare immunological responses to the
recombinant methylated HBHA produced in Mycobacterium
smegmatis [9], methylated synthetic peptides from HBHA, Purified
Protein Derivative (PPD), and the proteins with the documented
high specificity for M. tuberculosis infection ie. ESAT-6 and Culture
Filtrate Protein Derivative (CFP-10). For this pilot study we
enrolled a few tuberculosis (TB) patients with a variable degree of
disease activity and healthy young and middle-age Finnish
vaccinees who were practically free from any previous contact
with M. tuberculosis and thus served as a valid control group.
Methods
Human subjects and disease definitions
For this study we enrolled the subjects as follows:
a) Active TB group. Those subjects in whom the symptoms
of the disease started within one month, who were hospitalized,
anti-tuberculosis treatment was commenced within 2–3 weeks and
who had a recent positive bacteriological verification. In this group
four presented with pulmonary tuberculosis, one with tuberculosis
of gastrointestinal tract and one patient had tuberculosis of cervical
vertebra. In these subjects the blood samples were obtained within
the routine laboratory investigation.
b) Inactive TB group. This group consisted of outpatients
who presented with no or mild symptoms and who were either
partially treated for TB with PAS, streptomycin, and INH or
thoracotomy in forties and fifties, in whom chest X-ray findings
indicated lack of an active process. Patients with vertebral TB had
destructive processes of their vertebra at early childhood. At
adulthood their TB was confirmed by radiology and the thick
needle aspiration biopsy that ruled out other diseases. At the time
of investigation these patients did not receive anti-tuberculosis
treatment. Culture or nucleic acid amplification analysis (NAA)
were either negative or bacteriological analysis was not performed.
c) Disease control group. Four patients with pulmonary
manifestations in whom non-tuberculous mycobacterial (NTM)
infection was diagnosed by a positive culture isolation. At the time
of investigation these subjects were outpatients and their symptoms
were mild (mainly cough).
d) Healthy control group. Finnish-born University students
(mean age 25 years) who on the interview did not admit any previous
contact with a TB patient and thus served as an ideal negative
control, and Finnish-born laboratory personnel (mean age 50 years),
were enrolled. All subjects of this group were born after the routine
BCG vaccination campaign was implemented in Finland. Repeated
vaccinations were discontunued in Finland in 1990.
Ethical considerations
From the subjects of the group a) a verbal informed consent was
obtained. The verbal informed consent was sufficient because the
patient–doctor relationship was earlier established (Dr. Pusa), the
patients attended medical care for the routine doctor’s check-up
and venipuncture was a part of their current medical treatment.
From the groups b), c) and d) a written informed consent was
obtained before venipuncture. This study was approved by the
Ethical Committee of the University Hospital of Helsinki, Internal
Disease Department (Drno. 232/E5/07).
Sample processing
Whole blood was withdrawn and divided into portions. From
one portion sera were prepared by conventional methods and
frozen at 220uC until use. From another portion peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll Paque gradient
(Amersham Biosciences Inc., Piscataway, USA) and frozen in the
CTL (Cellular Technology Ltd., Cleveland, USA) media in a
liquid nitrogen until use. The characteristics of the individuals
enrolled in this study are presented in Table 1.
Synthetic peptides
Twenty three 15-mer sequential peptides overlapping by nine
amino acids and spanning the genomic sequence of the M.
tuberculosis (H37Rv) HBHA-protein starting from 37th amino acid
were synthesized (Proimmune, Oxford, UK; Alta Bioscience,
Birmingham, UK). The average purity of the peptides was ,73%.
Three peptides from the protein C-terminus were chemically
methylated at their lysine residues (see Legend of Fig. 3). The
methylation was done on the PEPscreen synthesis platform. Fmoc-
Lys(Me,Boc)-OH were pre-dissolved at a 0.5 M concentration,
placed on the deck, coupled and deprotected in the same way as
standard amino acids. Additionally, the peptides for serology were
biotinylated at their N-terminus. The quality control for all
peptides was accomplished by mass spectrometry analysis. The
peptides were dissolved in sterile asetonitrile and stored at 220uC
in aliquots of 1–4 mg/ml with ,30% glycerol for serology and in
PBS for the T-cell assays.
Recombinant HBHA antigen
Recombinant methylated HBHA was expressed in M. smegmatis
(rMtb-HBHA). The pMV3-38 plasmid that contained the full-
length HBHA open reading frame was kindly provided by Dr.G.
Delogu (University of Sassari, Sassari, Italy) [9]. The protein from
the bacterial extract was primarily purified by phosphocellulose
chromatography, i.e., cation exchange, because most mycobacte-
rial proteins do not bind to this resin at pH 7.0, and then further
purified by Ni-NTA chromatography [10]. This two-step
purification of rMtb-HBHA was highly effective. Contaminating
bands on PAGE gels stained with Coomassie blue were not
observed when 5–10 mg of the purified protein was loaded. The
purified protein was stored at 220uC in aliquots until use in
serology and T cell analysis.
T ELISPOT analysis
T-cell reactivity to ESAT-6, CFP-10 (the synthetic peptides
were from T-SPOT H-TB kit, Oxford Immunotec, Oxford, UK),
PPD (Statens Seruminstitut, Copenhagen, Denmark) and rMtb-
HBHA was assessed by Enzyme-Linked ImmunoSpot assay
(Mabtech Inc. Cincinnati, USA). Peripheral blood mononuclear
cells (PBMC) were purified from fresh blood samples by density
gradient centrifugation and stored with CryoABC Kit Freezing
media (Cellular Technology Ltd.) in liquid nitrogen until use. After
cells were washed with RPMI (HaartBio, Helsinki, Finland) and
resuspensed in the CTL Test Media (Cellular Technology Ltd.),
the cell count was performed by blood count-analyzer (ADVIA-60
Closed Tube Automated Haematology System, Bayer, Germany).
The cells were diluted at 2.56106 PBMC/ml in CTL Test Media
(Cellular Technology Ltd.). 250 000 PBMCs/well were stimulated
in ELISPOT-plates in the presence of synthetic peptide-pool
(10 mg/ml each), PPD (10 mg/ml), rMtb-HBHA (25 mg/ml). For
viability test 50 000 PBMC/well were stimulated with phyto-
haemagglutinin (PHA) (Oxford Immunotech). CTL Test Media
was used as a negative control. The plates were incubated at
+37uC with 5% CO2 for 48 h. Thereafter the plates were washed
and the analysis was performed according to the manufacturer’s
instruction. The spots were counted the ELISPOT-reader (Biosys,
Lyngby, Denmark) and the net values were calculated by
Diacnostic Utility of the HBHA
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subtracting the readings of the media control. Spot-sizes and the
cytokine values were examined with the ELISPOT-reader, AID
EliSpot Software Version 4.0 (AID GmbH, Strasburg, Germany).
The viability control test for the HBHA synthetic peptides was
performed by exposing PBMC to the CFP-10 peptide mixture
with asetonitrile added at concentrations of 15% and 30% (vs. only
2.5% in the final peptide solution). The addition of asetonitrile did
not violate the reactivity to the CFP-10 antigen (data not shown).
IgG and IgM determinations
The presence of IgG- and IgM-class antibodies to synthetic
peptides, rMtb-HBHA and PPD were determined by enzyme-
linked immunosorbent assay (ELISA). Synthetic peptides from
Borrelia burgdorferi VlsE-protein IR6 region and positive serum
samples from Lyme disease patients were used as the method
control [11]. 96-well microplates (Microlon high binding, Greiner,
Frickenhausen, Germany) were coated either with streptavidin
(Roche, Mannheim, Germany) in PBS, pH 7.5 (100 ng/well), or
PPD in PBS, pH 7.5 (1 mg/well), or with rMtb-HBHA in 0.1 M
bicarbonate buffer, pH 9.5 (250 ng/well) overnight at +4uC. The
plates were blocked with 0.25% Human serum albumin (HSA)
(Finnish Red Cross, Helsinki, Finland) in PBS for 1 h at +37uC and
washed four times with PBS containing 0.05% Tween20.
Biotinylated synthetic peptides (500 ng/well) and IR6 (200 ng/
well) in PBS, pH 7.5 were incubated for 2 h at room temperature.
Plates were washed as above and the human sera diluted 1:100 in
PBS containing 0.5% HSA, 10% FCS and 0.1% Tween20 and
were incubated for 2 h at room temperature. After wash Alkaline
phosphatase-conjugated anti-Human IgG or IgM antibody (Jackson
ImmunoResearch, W. Baltimore, USA) was added at 1:5 000
dilution in PBS containing 0.5% HSA and 0.1% Tween20. After
2 h of incubation at room temperature the plates were washed four
times. 4-nitrophenylphosphate (Boehringer Mannheim, Germany),
1 mg/ml in 0.1 M diethanolamine-0.5 mM MgCl2 was added to
each well and the reaction was stopped after 15 minutes with 0.1 M
NaOH. The plates were read at 405 nm with iEMS Reader MF
(Labsystems, Helsinki, Finland). IgM rheumatoid factor was
controlled for all serum samples by immunonephelometric method
at the HUSLAB, Unit of Immunology.
Statistical analysis
The correlation was analyzed by the non-parametric Spearman
test. The Receiver operating characteristic (ROC) curve analysis and
the Area under the curve (AUC) with respective 95% confidence
intervals (CI) for each antigen were calculated with the GraphPad
Prism version 4.0 (GraphPad Software, Inc. San Diego, CA).
The amino acid sequences of the HBHA from M. tuberculosis and
M. bovis were searched with the Entrez Protein search engine and
then the sequences were aligned with the Needle program,
EBLOSUM62-Matrix (EMBOSS, [12]).
Results
Cell-mediated immunity
Employing both techniques for immune reactivity study of
rMtb-HBHA, we observed considerable interindividual variation
in all studied groups (Fig. 1A–C and Fig. 3 A–B; D–F). These
observations hold true irrespective of the measured parameters of
immunoreactivity; neither the numbers of reactive cells, nor the
amount of the IFNc released, nor the optical densities in the IgG
and IgM EIAs were discriminatory when comparing the groups.
For example, the highest values of 430, 387, and 360 reactive
cells/106 lymphocytes were observed in the groups of active TB,
inactive TB and healthy vaccinees, respectively. Strikingly, half of
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the vaccinated persons reacted strongly against rMtb-HBHA and
the reactivities were equally high as those of the TB-patients
(Fig. 1A). When the comparisons between the groups were done
by semiquantitative calculation of the amount of the produced
cytokine, ie. the size and the intensity of the spot, the highest
median value of the cytokine production was found in the
vaccinated group (Fig. 1B). Persons with positive environmental
mycobacteria culture result reacted similarly as the persons from
other groups with a high interindividual variation (Fig. 1A and B).
Positive correlation was observed then the reactivities to rMtb-
HBHA and PPD, an indicator of vaccination or infection, were
compared for all the tested samples (Fig. 1D). One healthy 60-
year-old individual who was not vaccinated in his childhood
showed humoral and cell-mediated immune responses to rMtb-
HBHA as measured by both EIAs and ELISPOT assay, indicating
immunization with so-called atypical mycobacteria. Noteworthy,
this person had a negative tuberculin skin test and his lymphocytes
did not recognise ESAT-6 and CFP-10 peptide mixtures in
ELISPOT (data not shown). Furthermore, the obtained reactiv-
ities were reproducible and the measurements did not exceed the
expected between-run imprecisions of CV% #15 and #40% for
EIAs and ELISPOT, respectively. When the frequencies of
reactive cells were compared between persons of different ages,
no differences were noticed either (Fig. 1C), indicating that there
was no waning of immunological memory towards HBHA with
age. In other words, ELISPOT analysis produced similar patterns
of reactivities between the studied groups with 2 out of 5; 3 out of
6; and 7 out of 15 being strong reactors in the groups of inactive
TB, active TB, and vaccinees, respectively (Fig. 1A).
As expected, when tested concurrently with a mixture of specific
peptides derived from ESAT-6 and CFP-10 of M. tuberculosis,
samples from patients with active and inactive TB did react in the
ELISPOT assay, whereas samples from all healthy individuals, did
not (Fig. 2 A and B).
Humoral immunity to HBHA
High interindividual variations were observed in serology, ie. 3
out of 9 (Inactive TB) and 2 out of 4 (Active TB) were strong
reactors in the IgG and IgM EIA whereas almost all vaccinees
showed moderate to high reactivities in IgG and IgM EIAs
(Fig. 3A–B, D–F). Noteworthy, the median value of IgM
antibodies to rMtb-HBHA was the highest in the group of healthy
BCG-vaccinated individuals. Synthetic peptides were not recog-
nised by any of the tested sera in the IgG EIA (data not shown).
When tested for IgM rheumatoid factor it was detectable only in
one person in the TB-patients group. Interestingly, IgM-class
antibodies were detectable in almost all of the individuals in the
study, with an exception of two non-vaccinated infants (data not
shown). The IgM-class antibodies recognised not only rMtb-
HBHA but also the three 15-mer linear methylated peptides from
the HBHA C-terminus (Fig. 3D–F). We believe that IgM-class
antibodies alone reacting to the C-terminal peptides of HBHA
probably indicate a non-specific reaction arising from heterophilic
antibodies, for example, or immunological cross-reactivity with
Figure 1. The ability of rMtb-HBHA and PPD to induce the production of IFNc was tested in the ELISPOT technique. The groups of
patients with inactive TB (n = 5); active TB (n = 6), healthy young (n = 7) and middle-age (n = 8) vaccinated subjects and patients with isolation of so-
called atypical mycobacteria (n = 4) and were enrolled. Comparison of the cell-mediated immunological responses to rMtb-HBHA was performed as
the determination of the number of reactive cells per106 lymphocytes (A) and as the measurement of IFNc production activities expressed as
arbitrary units (B). Cell-mediated immunological responses in healthy vaccinated individuals was studied by division by age into two groups (C). The
correlation of rMtb-HBHA with the PPD ELISPOT reactivities expressed as the frequencies of reactive cells per106 is presented in (D). Data are shown
as individual reactivities; the horizontal bars represent arithmetic median values.
doi:10.1371/journal.pone.0003272.g001
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conserved sequences of environmental bacteria (e.g., rhodococcus,
http://www.ncbi.nlm.nih.gov/blast/Blast.cg).
Comparison of the discriminatory power of rMtb-HBHA,
PPD, ESAT-6 and CFP-10
ROC curves were constructed for all tested antigens and the AUCs
with respective 95% CI were compared for each tested antigen
(Fig. 4A–D). As expected, ESAT-6 and CFP-10 produced ROC
curves acceptable for diagnostics with AUCs ranging from 0.947 to
0.972 and a narrow 95% CI (0.84–1.052) (Fig. 4C–D). On the
contrary, the AUC for rMtb-HBHA (0.636; 95% CI 0.391–0.886)
was comparable to the one for PPD (0.736; 95%CI 0.531–0.941)
(Fig. 4A–B) indicating in practice no discriminatory power between
healthy vaccinees and persons with a TB infection. As a consequence
of high interindividual variation in rMtb-HBHA immunoassays, the
confidence interval for the respective AUC was wide.
Discussion
The potential of HBHA for diagnostics have been recently
reported [3,5,6,7,10,13]. In this pilot investigation we attempted to
Figure 2. Production of IFNc by lymphocytes stimulated with ESAT-6 (Panel A) and CFP-10 (Panel B) was tested in the ELISPOT
technique. The groups of patients with inactive TB (n = 5), active TB (n = 6) and healthy vaccinated subjects (n = 13) were tested. Cell-mediated
immunological responses were determined as the number of reactive cells per 106 lymphocytes. The lower dotted line is the level of positivity
suggested by the manufacturer, the upper dotted line is the level of positivity adopted at the HUSLAB diagnostic laboratory. The area between the
two dotted lines represents the so-called grey-zone, an area of uncertainty for interpretation that was calculated based on assay imprecision (data not
published).
doi:10.1371/journal.pone.0003272.g002
Figure 3. The serological reactivities to synthetic peptides, rMtb-HBHA and PPD were tested in IgG and IgM ELISAs. The groups of
patients with inactive TB (n = 9), active TB (n = 4) and healthy vaccinated individuals (n = 4) were enrolled. Serological responses to rMtb-HBHA
measured by the IgG EIA (A), IgM EIA (B), and IgG correlation in the PPD and rMtb-HBHA ELISAs (C). IgM responses to methylated 15-mer linear
peptides from the C terminus of HBHA: IELPKKAAPA[KMe]KAAP (D), AAPAKKAAPA[KMe]KAAA (E), and AAPAKKAAPA[KMe][KMe]AAA (F). Individual
responses are presented as optical densities (OD405). The horizontal bars represent arithmetic median values.
doi:10.1371/journal.pone.0003272.g003
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have an insight into the usefulness of this antigen for diagnostics in
our fully vaccinated population. We aimed to compare immuno-
reactivity to rMtb-HBHA and HBHA methylated synthetic
peptides with the immunoreactivity to the conventional PPD that
have been used for decades with poor success because of inability
to discriminate TB infection from immunity caused by vaccina-
tion. For comparison, we used two other secreted antigens, namely
ESAT-6 and CFP-10. These antigens have been proven highly
immunogenic and specific for M. tuberculosis infection and are
absent from the majority of non-tuberculous mycobacteria and
BCG substrain [for review see 1]. The major objective was to
investigate whether immunological responses in persons with a
proven contact with M. tuberculosis (Active and Inactive TB groups)
would be quantitatively and qualitatively different from vaccinated
individuals. In other words, we were interested to study the
specificity of immune response to HBHA as a nominator of
infection. The minor objective was to see whether immunological
responses would differ in TB patients with a different degree of
disease severity. We did not enrol a group of patients with a
proven LTBI which may be considered as a limitation of our
study. On the contrary, we enrolled young Finnish vaccinees that
were unambiguously interpreted as free from LTBI and some
patients with proven NTM infection. In our opinion, these two
groups is a strength of our investigation. For analysis we used
ELISPOT and EIA techniques.
The rMtb-HBHA antigen used in this study was prepared as
described by Delogu et al [9]. Using a limited clinical material we
were not able to affirm the discriminatory power of rMtb-HBHA
in serology. Zanetti et al [6] who referred to the same method of
the recombinant HBHA expressed in M. smegmatis [9], showed that
only forty-four out of 111 sera with active TB produced optical
densities over the presumed cut-off level of 0.5 OD(405nm). In their
study, surprisingly, the combined group of vaccinated people and
patients with presumed latent tuberculosis infection did not
produce IgG reactivities above the cut-off level. Using a larger
cohort size than we did, Zanetti et al. [6] demonstrated a trend
towards higher frequencies of responders in IgG serology in
patients with active TB, however only 1/3 of the tested subjects
were classified as serology positive. It seems however, that this
frequency of positive results would not satisfy diagnostic needs. In
our investigation we were able to detect IgM antibodies that
recognized rMtb-HBHA and synthetic peptides of the C-terminus
practically from all the tested individuals and also from one 60-
year-old person who has never been vaccinated nor has a LTBI
(data not shown). In the study of Shin et al. [10] who used
immunoblot and EIA techniques to investigate IgM reactivity to
rMtb-HBHA, the antibodies were detectable in early and chronic
TB patients whereas healthy students, the controls, were non-
responders. In their study, however, the vaccination status of the
controls was not reported, therefore we are left with uncertainty
how would this antigen be recognised in BCG vaccinees.
Masungi et al. [5] used HBHA that was purified from a BCG
substrain. As others, they also reported that negative control
subjects and the BCG vaccinees did not produce anti-HBHA
antibodies at detectable level and the reactivity towards HBHA in
lymphocyte stimulation assay was non-significant. On the
contrary, when lymphocytes were stimulated with PPD, the
controls and the BCG vaccinees reacted strongly [5]. In the most
recent study of Hougardy et al. [7] HBHA was also purified from a
BCG substrain and the cell-mediated immunity was studied as
Figure 4. ROC curves were constructed to compare ELISPOT results when the cells were stimulated with rMtb-HBHA (A), PPD (B),
and peptide mixtures of ESAT-6 and CFP-10 (C–D). The curves were established for infected (Active and Inactive TB) and the healthy control
group. The calculated AUC and the respective confidence intervals (in brackets) are shown for each tested antigen.
doi:10.1371/journal.pone.0003272.g004
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Masungi et al. by lymphocyte stimulation and a subsequent
measurement of secreted interferon gamma (IFNc). In their study
the authors used control subjects who had no history of a TB
contact but in whom half were BCG vaccinated. Quite opposite to
our findings they observed the steepest ROC when lymphocytes
were stimulated with HBHA while the stimulation with ESAT-6
produced the least discriminatory ROC.
Methylation of HBHA is crucial for effective T-cell immunity.
Thus, native HBHA purified from BCG or M. tuberculosis H37Ra
evoked a much stronger CD8+ and CD4+ mediated immune
responses than the recombinant non-methylated HBHA produced
in E. coli [13]. However, as indicated, recombinant M. smegmatis
expression host was able to produce HBHA with a methylation
pattern very similar to that of the native HBHA, as was evidenced
by mass spectrometry analysis, amino acid sequencing, electropho-
resis and recognition by the same monoclonal antibody [14]. There
is however a possibility that folding of native HBHA produced by
BCG or M. tuberculosis and of recombinant HBHA produced in M.
smegmatis may be different which would cause minor differences in
their immunoreactivities. The protein used in our study, rMtb-
HBHA, was expressed inM. smegmatis and all attempts were made to
avoid potential contamination that might have blurred the results.
While it could be argued that minor M. smegmatis genome coded
contaminant antigens might have caused the observed T cell
responses in our study, the antibody responses (IgM) to the synthetic
peptides support the view of weak specificity of the rMtb-HBHA
responses in BCG vaccinated persons. In view of a longevity of
immunological memory even without boosting [15,16] it is not
unexpected that our healthy vaccinees recognised rMtb-HBHA that
has a 95.5% amino acid sequence homology to BCG HBHA [12].
Results of immunological studies with a battery of synthetic
peptides comprising mono- and dimethylated peptides of the C-
terminus of HBHA were very disappointing. In this study IgM-
class reactivities were detectable but in a very unpredictable
fashion while IgG-class antibodies did not recognize peptides even
methylated ones in any of the patient groups. The peptides did not
evoke any T cell mediated response. Noteworthy, our study
protocol confirmed that the non-responsiveness to the peptides
was not attributed to the toxicity of asetonitrile used in the peptides
solution. Temmerman et al [13] studied T cell immunity with a
peptide scan analysis first with non-methylated peptides and then
probing a methylated peptide. Only one non-methylated peptide
produced some IFNc in a portion of LTBI patients. The
reproducibility of this finding was not, however, reported. In their
hands the methylated peptide induced also some IFNc production
but only in combination with the recombinant protein. The
authors speculated that the methylated peptide might need a
protein carrier. We too have no solid explanation why synthetic
peptides behaved so differently in cell mediated and humoral
immunity studies compared to the recombinant protein. In fact,
we know yet little about how the HBHA is chopped in the
lysosome and how the methylated antigens are presented by MHC
II molecules.
Because our cohorts were too small to be able to pick-up minor
differences in reactivity between the studied subjects we chose to
use ELISPOT, the most sensitive and functional technique to
study cell-mediated immunity. We assessed not only the
frequencies of reactive lymphocytes (Fig. 1A) but the production
of IFNc as well (Fig. 1B). In this way we tried to do the analysis as
close as feasible to that of Masungi et al. and Hougardy et al.
However, in neither of the analyses could we prove HBHA
superiority over the well-established antigens for diagnostics,
namely ESAT-6 and CFP-10. As expected, these latter antigens
possessed sufficient discriminatory power to separate infected
individuals from vaccinated persons (Fig. 2A–B). The ROC
analysis with a narrow 95% CI confirmed this conclusion (Fig. 4A–
D). In fact, recent study by Chee et al. [17] showed that the two
commercial methods for TB immunodiagnostics produced a poor
agreement (k=0.257) when testing 270 patients with pulmonary
TB. One was an ELISPOT- and the other was an EIA-based
method. The authors speculated that the differences in results may
be attributed to heterophilic antibody effects, non-specific IFNc in
the blood samples and lack of standardised lymphocyte counts in
EIA-based technology compared to ELISPOT. The factors
mentioned by Chee et al. [17] may also contribute to controversy
between our pilot study and earlier studies [5,7] where EIA-based
methods have been applied.
This pilot study casts some concerns about the possibility to
generalize about diagnostic potential of HBHA. We have observed
that samples from healthy individuals in a country with almost
complete vaccination coverage and even from individuals who
have never been vaccinated may exhibit immune reactivities to
HBHA, indicating that natural immunization to this protein or to
cross-reactive peptides may occur. Therefore, on the basis of i) the
presence of closely related antigen in a BCG substrain; ii) observed
good correlation with PPD in serology and cell-mediated assays,
iii) comparable ROC analysis for HBHA and PPD; iv) evidence of
reactivities of vaccinees without any previous risk of contraction of
M. tuberculosis infection, HBHA by no means is superior to ESAT-6
and CFP-10. In our environment HBHA practically does not add
to tuberculosis immunodiagnostics. In conclusion, our results
emphasize that the search for new more promising antigens for TB
diagnostics should continue.
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